Pharmacoeconomic Spotlight on Varenicline as an Aid to Smoking Cessation

Keating, Gillian M.; Lyseng-Williamson, Katherine A.
September 2010
CNS Drugs;2010, Vol. 24 Issue 9, p797
Academic Journal
Varenicline (Chantix®, Champix®) is an orally administered α4β2 nicotinic acetylcholine receptor partial agonist that is indicated as an aid to smoking cessation. Varenicline was an effective aid to smoking cessation and was generally well tolerated in clinical trials, although more data are needed regarding the potential for neuropsychiatric events. The costs associated with varenicline are offset by direct savings associated with the reduction in smoking-related diseases. Indeed, despite their limitations, available pharmacoeconomic analyses from numerous countries support the use of varenicline for 12 or 24 weeks as a cost-effective treatment relative to other smoking cessation therapies in smokers who wish to quit smoking. For example, in modelled cost-effectiveness analyses conducted from a healthcare payer perspective, 12 weeks' treatment with varenicline consistently dominated bupropion sustained release and nicotine replacement therapy, and was dominant over, or considered cost effective relative to, unaided cessation, brief counselling or nortriptyline, with regard to the incremental costs per quality-adjusted life-year or life-year gained.


Related Articles

  • Chantix Approved for Smoking Cessation.  // Journal of Psychosocial Nursing & Mental Health Services;Jul2006, Vol. 44 Issue 7, p45 

    Reports on the approval by the U.S. Food and Drug Administration for Chantix, a novel medication for smoking cessation. Mechanism of action of the varenicline tartrate tablets; Clinical trials on the drug.

  • Carbidopa/levodopa for smoking cessation: a pilot study with negative results. Hurt, Richard D.; Ahlskog, J. Eric; Croghan, Gary A.; Offord, Kenneth P.; Wolter, Troy D.; Croghan, Ivana T.; Moyer, Thomas P.; Hurt, R D; Ahlskog, J E; Croghan, G A; Offord, K P; Wolter, T D; Croghan, I T; Moyer, T P // Nicotine & Tobacco Research;Feb2000, Vol. 2 Issue 1, p71 

    The mesolimbic dopamine system is thought to be a critical substrate for drugs of addiction including nicotine. Since dopamine may play a critical role in mediating the reinforcing effects of nicotine, we hypothesized that administering levodopa in its therapeutic form (carbidopa/levodopa) might...

  • Contingency management and motivational enhancement: A randomized clinical trial for college student smokers. Tevyaw, Tracy O'L.; Colby, Suzanne M.; Tidey, Jennifer W.; Kahler, Christopher W.; Rohsenow, Damaris J.; Barnett, Nancy P.; Gwaltney, Chad J.; Monti, Peter M. // Nicotine & Tobacco Research;Jun2009, Vol. 11 Issue 6, p739 

    Introduction: The efficacy of contingency-management (CM) and motivational enhancement therapy (MET) for college student smoking cessation was examined.

  • Giving up smoking is easier for patients with access to telephone counselling.  // BMJ: British Medical Journal (International Edition);4/29/2006, Vol. 332 Issue 7548, p982 

    The article summarizes a research study on the effects of telephone counseling for smoking cessation programs. The study found that periodic calls from a counselor worked more effectively than advice given by a primary care doctor during routine visits. The researchers found people who wanted to...

  • Cutting the last cigarette: Are we ready to give patients the perfect solution? Diamantouros, Artemis // Canadian Pharmacists Journal;May/Jun2010, Vol. 143 Issue 3, p148 

    The article explores a study entitled "A Randomized Placebo-Controlled Clinical Trial of 5 Smoking Cessation Pharmacotherapies," by M. E. Piper and colleagues. According to the study, nicotine patch plus lozenge group had the strongest support, with an odds ratio (OR) of 2.34. The study...

  • Recurrent event analysis of lapse and recovery in a smoking cessation clinical trial using bupropion. Wileyto, E. Paul; Patterson, Freda; Niaura, Raymond; Epstein, Leonard; Brown, Richard; Audrain-McGovern, Janet; Hawk Jr., Larry W.; Lerman, Caryn; Epstein, Leonard H; Brown, Richard A; Hawk, Larry W Jr // Nicotine & Tobacco Research;Apr2005, Vol. 7 Issue 2, p257 

    We report a reanalysis of data from a prior study describing the event history of quitting smoking aided by bupropion, using recurrent-event models to determine the effect of the drug on occurrence of lapses and recoveries from lapse (resumption of abstinence). Data were collected on 1,070...

  • Use of Stop-Smoking Medications Before and After Introduction of Varenicline in the United States and United Kingdom.  // MD Conference Express;Jun2009, p12 

    The article discusses the effects of Varenicline, a new prescription stop-smoking medication (SSM) that was used in the U.S. and Great Britain since 2006. It states that the medication has greater clinical efficacy than other stop-smoking medications (SSMs). It highlights the report of Cheryl...

  • Trials that Matter: Varenicline: A Designer Drug to Help Smokers Quit. Schroeder, Steven A.; Sox, Harold C. // Annals of Internal Medicine;11/21/2006, Vol. 145 Issue 10, p784 

    The article reflects on a study about the role of varenicline on smoking cessation treatment. The study is a multicenter randomized doubleblind placebo-controlled trial which compared the effectiveness of varenicline with placebo and buproprion SR in treating smokers. In line with that, the...

  • Effects of continuous nicotine infusion on nicotine self-administration in rats: relationship between continuously infused and self-administered nicotine doses and serum concentrations. LeSage, Mark G.; Keyler, Daniel E.; Collins, Greg; Pentel, Paul R. // Psychopharmacology;2003, Vol. 170 Issue 3, p278 

    Rationale. The efficacy of nicotine replacement therapy (NRT) for smoking cessation is limited. One reason for this limited efficacy may be that typical serum nicotine concentrations provided by NRT do not match the peak arterial nicotine concentrations achieved from smoking. Objective. The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics